Does anyone know the level of disclosure that will occur at the presentation? One item I am specifically curious about if they will indicate how many of those who did not get SVR's failed to do so because of mutations (according to Intermune presentations 950 had poor resistance against the NS3 A156T Variant).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.